Roche Launches Digital PCR System
Roche’s Digital LightCycler System is designed to aid in diagnostics for cancer, genetic disease, and infection.
Roche recently announced the launch of its first digital polymerase chain reaction (PCR) system, the Digital LightCycler System (DLS). The DLS is designed to detect disease and accurately quantify trace amounts of specific DNA and RNA targets that are not typically detectable by conventional PCR methods.
According to an Aug. 23, 2022 press release, the DLS will allow clinical research to divide DNA and RNA from a clinical sample into up to 100,000 microscopic individual reactions. This provides opportunities for high precision analysis, including identifying ultra-rare targets or accurately quantifying how much of the target DNA/RNA there is at a molecular level.
"Understanding the hidden characteristics of serious diseases is fundamental for ensuring that the most effective treatment is selected for each patient," said Thomas Schinecker, CEO, Roche Diagnostics, in the press release. “The Digital LightCycler System will support clinical researchers and laboratories in identifying rare and emerging disease mutations. This can be instrumental in early diagnosis and therapy decisions."
Source: Roche
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.
